A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer

Ekaterina Revskaya, Zewei Jiang, Alfred Morgenstern, Frank Bruchertseifer, Muctarr Sesay, Susan Walker, Steven Fuller, Michael S. Lebowitz, Claudia Gravekamp, Hossein A. Ghanbari, Ekaterina Dadachova

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer. PAN-622 was conjugated to several ligands such as DOTA, CHXA″, and DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAH-specific enzyme-linked immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary tumor-bearing BALB/c mice. The 111In-DTPA-pan622 mAb concentrated in the primary tumors and to some degree in lung metastases as shown by SPECT/CT and Cherenkov imaging. A pilot therapy study with 213Bi - DTPA-PAN-622 demonstrated a significant effect on the primary tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising reagent for development of imaging and possible therapeutic agents for the treatment of metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)57-65
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Volume32
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Mixed Function Oxygenases
Pentetic Acid
Breast Neoplasms
Antibodies
Monoclonal Antibodies
Therapeutics
Neoplasms
Radioimmunotherapy
Epidermal Growth Factor
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Ligands
Lung
Enzymes
Proteins

Keywords

  • In, Bi, HAAH, metastatic breast cancer, PAN-622 human antibody, radioimmunotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer. / Revskaya, Ekaterina; Jiang, Zewei; Morgenstern, Alfred; Bruchertseifer, Frank; Sesay, Muctarr; Walker, Susan; Fuller, Steven; Lebowitz, Michael S.; Gravekamp, Claudia; Ghanbari, Hossein A.; Dadachova, Ekaterina.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 32, No. 2, 01.03.2017, p. 57-65.

Research output: Contribution to journalArticle

Revskaya, E, Jiang, Z, Morgenstern, A, Bruchertseifer, F, Sesay, M, Walker, S, Fuller, S, Lebowitz, MS, Gravekamp, C, Ghanbari, HA & Dadachova, E 2017, 'A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer', Cancer Biotherapy and Radiopharmaceuticals, vol. 32, no. 2, pp. 57-65. https://doi.org/10.1089/cbr.2016.2141
Revskaya, Ekaterina ; Jiang, Zewei ; Morgenstern, Alfred ; Bruchertseifer, Frank ; Sesay, Muctarr ; Walker, Susan ; Fuller, Steven ; Lebowitz, Michael S. ; Gravekamp, Claudia ; Ghanbari, Hossein A. ; Dadachova, Ekaterina. / A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer. In: Cancer Biotherapy and Radiopharmaceuticals. 2017 ; Vol. 32, No. 2. pp. 57-65.
@article{413ef0d6af85404e9ae25a808eb089b0,
title = "A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer",
abstract = "There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer. PAN-622 was conjugated to several ligands such as DOTA, CHXA″, and DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAH-specific enzyme-linked immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary tumor-bearing BALB/c mice. The 111In-DTPA-pan622 mAb concentrated in the primary tumors and to some degree in lung metastases as shown by SPECT/CT and Cherenkov imaging. A pilot therapy study with 213Bi - DTPA-PAN-622 demonstrated a significant effect on the primary tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising reagent for development of imaging and possible therapeutic agents for the treatment of metastatic breast cancer.",
keywords = "In, Bi, HAAH, metastatic breast cancer, PAN-622 human antibody, radioimmunotherapy",
author = "Ekaterina Revskaya and Zewei Jiang and Alfred Morgenstern and Frank Bruchertseifer and Muctarr Sesay and Susan Walker and Steven Fuller and Lebowitz, {Michael S.} and Claudia Gravekamp and Ghanbari, {Hossein A.} and Ekaterina Dadachova",
year = "2017",
month = "3",
day = "1",
doi = "10.1089/cbr.2016.2141",
language = "English (US)",
volume = "32",
pages = "57--65",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer

AU - Revskaya, Ekaterina

AU - Jiang, Zewei

AU - Morgenstern, Alfred

AU - Bruchertseifer, Frank

AU - Sesay, Muctarr

AU - Walker, Susan

AU - Fuller, Steven

AU - Lebowitz, Michael S.

AU - Gravekamp, Claudia

AU - Ghanbari, Hossein A.

AU - Dadachova, Ekaterina

PY - 2017/3/1

Y1 - 2017/3/1

N2 - There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer. PAN-622 was conjugated to several ligands such as DOTA, CHXA″, and DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAH-specific enzyme-linked immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary tumor-bearing BALB/c mice. The 111In-DTPA-pan622 mAb concentrated in the primary tumors and to some degree in lung metastases as shown by SPECT/CT and Cherenkov imaging. A pilot therapy study with 213Bi - DTPA-PAN-622 demonstrated a significant effect on the primary tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising reagent for development of imaging and possible therapeutic agents for the treatment of metastatic breast cancer.

AB - There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer. PAN-622 was conjugated to several ligands such as DOTA, CHXA″, and DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAH-specific enzyme-linked immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary tumor-bearing BALB/c mice. The 111In-DTPA-pan622 mAb concentrated in the primary tumors and to some degree in lung metastases as shown by SPECT/CT and Cherenkov imaging. A pilot therapy study with 213Bi - DTPA-PAN-622 demonstrated a significant effect on the primary tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising reagent for development of imaging and possible therapeutic agents for the treatment of metastatic breast cancer.

KW - In, Bi, HAAH, metastatic breast cancer, PAN-622 human antibody, radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85015641146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015641146&partnerID=8YFLogxK

U2 - 10.1089/cbr.2016.2141

DO - 10.1089/cbr.2016.2141

M3 - Article

C2 - 28301261

AN - SCOPUS:85015641146

VL - 32

SP - 57

EP - 65

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 2

ER -